Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of “Moderate Buy” from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $40.8182.

A number of equities research analysts have recently commented on the stock. B. Riley reaffirmed a “buy” rating and issued a $50.00 target price (up from $21.00) on shares of Capricor Therapeutics in a report on Monday, December 15th. Industrial Alliance Securities set a $48.00 price target on Capricor Therapeutics in a research report on Wednesday, December 3rd. Roth Capital upped their price objective on Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Oppenheimer increased their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Finally, Maxim Group boosted their target price on Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, December 4th.

Capricor Therapeutics Stock Down 1.9%

Shares of NASDAQ CAPR opened at $28.31 on Monday. The business has a 50-day moving average price of $16.05 and a 200 day moving average price of $10.51. The stock has a market cap of $1.29 billion, a PE ratio of -15.73 and a beta of 0.22. Capricor Therapeutics has a 52-week low of $4.30 and a 52-week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). Sell-side analysts anticipate that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently bought and sold shares of CAPR. PVG Asset Management Corp purchased a new stake in shares of Capricor Therapeutics in the third quarter valued at about $91,000. Voleon Capital Management LP purchased a new position in Capricor Therapeutics during the third quarter worth about $311,000. Moneta Group Investment Advisors LLC lifted its position in Capricor Therapeutics by 25.5% in the third quarter. Moneta Group Investment Advisors LLC now owns 34,454 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 7,000 shares during the period. Brevan Howard Capital Management LP acquired a new stake in Capricor Therapeutics in the third quarter valued at about $123,000. Finally, Raymond James Financial Inc. boosted its holdings in Capricor Therapeutics by 1,629.9% in the 3rd quarter. Raymond James Financial Inc. now owns 191,292 shares of the biotechnology company’s stock valued at $1,379,000 after purchasing an additional 180,234 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.